Cesca Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference
August 30 2018 - 8:30AM
Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in
automated cell processing and point-of-care, autologous cell-based
therapies, today announced that Chris Xu, PhD, chief executive
officer, will present at the H.C. Wainwright 20th Annual Global
Investment Conference on Thursday, September 6, 2018 at 11:40am ET.
The conference is being held September 4-6 at the St. Regis in New
York City.
Management will also be available for one-on-one
meetings with institutional investors who are registered to attend
the conference. If you are an institutional investor and would like
to attend Cesca’s presentation or meet with management, please
click on the following link (www.rodmanevents.com) to register.
Once confirmed, you will be prompted to log into the conference
website to request a one-on-one meeting with the Company.
A link to the live webcast of the presentation
will be in the Investors section on the Events and Webcast page of
the Company’s website: www.cescatherapeutics.com. The webcast will
be archived for 90 days.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (the “Company”)
develops, commercializes and markets a range of automated
technologies for CAR-T and other cell-based therapies. Its device
division, ThermoGenesis Corp., provides a full suite of solutions
for automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology. The Company is developing an
automated, functionally-closed CAR-TXpress™ platform to streamline
the manufacturing process for the emerging CAR-T immunotherapy
market.
Forward-Looking StatementThe
statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. A more complete description of risks
that could cause actual events to differ from the outcomes
predicted by Cesca Therapeutics' forward-looking statements is set
forth under the caption "Risk Factors" in Cesca Therapeutics’
annual report on Form 10-K and other reports it files with the
Securities and Exchange Commission from time to time, and you
should consider each of those factors when evaluating the
forward-looking statements.
Company Contact: Cesca Therapeutics Inc. Wendy
Samford916-858-5191ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024